NCT05024045 2026-03-03Study of Oral LOXO-338 in Patients With Advanced Blood CancersEli Lilly and CompanyPhase 1 Active not recruiting316 enrolled
NCT04849416 2026-02-06A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)Eli Lilly and CompanyPhase 2 Completed87 enrolled 19 charts
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT07162181 2026-01-21Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersEli Lilly and CompanyPhase 2 Recruiting13 enrolled
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA